David Lebwohl - 01 Jan 2024 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, Chief Medical Officer
Signature: James Basta, attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 01 Jan 2024
Net transactions value: $0
Form type: 4
Filing time: 03 Jan 2024, 17:34:10 UTC
Previous filing: 03 Mar 2023
Next filing: 05 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Options Exercise		+3,187	+5.6%		60,215	01 Jan 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Restricted Stock Unit	Options Exercise	$0	-3,187	-50%	$0.000000	3,189	01 Jan 2024	Common Stock	3,187		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2	Includes 360 and 307 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2023 and December 31, 2023, respectively.
F3	On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.